Company intelligence / Profile preview

Pier 88 Health

Redwood City, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Pier 88 Health has launched a comprehensive digital health ecosystem in China focused on chronic pain and migraine, integrating telemedicine, AI-driven decision support, and recently received NMPA approval to commercialize the Nerivio REN wearable device for acute migraine treatment. This is the first NMPA-approved REN-based migraine device in China, and part of a partnership with Theranica. Nerivio is supported by global clinical data and offers drug-free, non-invasive treatment for acute and preventive migraine with robust real-world use in multiple regions.[2][5]

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Theranica

Beyond the preview

Go deeper on Pier 88 Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pier 88 Health.

Explore the full profile